D. E. Shaw & Co., Inc. I Mab Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.08 - $7.39 $247,182 - $593,077	-80,254 Reduced 82.29%	17,266 $59,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $4.86 $20,366 - $30,739	6,325 Added 6.94%	97,520 $407,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $88,600 - $272,652	22,095 Added 31.98%	91,195 $366,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $108,328 - $241,414	-13,099 Reduced 15.94%	69,100 $781,000
Q1 2022 May 16, 2022	BUY	$12.54 - $46.93 $212,101 - $793,774	16,914 Added 25.91%	82,199 $1.34 Million
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $7.06 Million - $11.6 Million	-155,996 Reduced 70.5%	65,285 $3.09 Million
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $3.59 Million - $5.3 Million	62,823 Added 39.65%	221,281 $16 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $5.77 Million - $10.1 Million	120,642 Added 319.02%	158,458 $13.3 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $1.68 Million - $2.42 Million	37,816 New	37,816 $1.83 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.